We aimed to assess the effectiveness of cyclophosphamide, etoposide and G-CSF (C+E) to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. A matched cohort study was performed comparing patients mobilized with C+E to patients mobilized with cyclophosphamide and G-CSF (C alone). Patients were matched for disease, prior radiotherapy and a chemotherapy score reflecting the amount and type of prior chemotherapy. Thirty-eight consecutive patients mobilized with C+E were compared with 38 matched controls. C+E was equivalent to C alone in terms of numbers of patients achieving a minimum threshold of у2 ؋ 10 6 /kg CD34 + cells (82% vs 79%, P = 0.74). C+E was superior, however, in terms of total CD34 + yield (6.35 vs 3.3 ؋ 10 6 /kg, P Ͻ 0.01), achieving a target graft of у5 ؋ 10 6 /kg (55% vs 34%, P = 0.04) and obtaining both a minimum (61% vs 32%, P Ͻ 0.01) and target (45% vs 13%, P Ͻ 0.01) graft in one apheresis. This superiority was largely confined to patients with lower chemotherapy scores. There was no difference in neutrophil and platelet recovery or transfusion requirements for those who subsequently received high-dose therapy and stem cell transplantation. Thus, C+E improves the efficiency of peripheral blood stem cell collection, but does not increase the number of patients who can proceed to transplantation. Most of the benefit of the regimen was confined to patients who had not received extensive prior therapy. Novel strategies are required to increase the collection efficiency of 'hard to mobilize' patients. 
in patients with lymphoma. Engraftment following transplantation of PBSCs is more rapid than with bone marrow 1 and has been demonstrated to correlate best with the number of CD34
+ cells in the graft. With standardization of CD34 + enumeration, 2 у5 ϫ 10 6 /kg CD34 + cells has been suggested as a reasonable target for PBSC collection, as this allows optimal engraftment in nearly all patients. [3] [4] [5] Alternatively, transplantation of Ͻ1 to 2 ϫ 10 6 /kg CD34 + cells has been associated with delayed and failed engraftment, [6] [7] [8] [9] [10] leading to the concept of a minimum threshold CD34
+ count in order to safely proceed with ASCT. Optimizing PBSC collection remains an important goal for several reasons: to increase the proportion of patients who can proceed to ASCT; to reduce the time to hematopoietic recovery post transplant; to maximize the efficiency of the PBSC collection process given the morbidity and costs of apheresis; and to reduce the need for second mobilizations and bone marrow harvests. Several studies 5, [11] [12] [13] [14] have described factors influencing the yield of PBSCs, including age, diagnosis, marrow involvement, prior radiation and time from prior chemotherapy therapy, but amount of previous chemotherapy seems to be the most consistent. The prior use of stem cell toxic regimens or agents such as nitrogen mustard, procarbazine, melphalan, carmustine, high-dose cytarabine, 15 Dexa-BEAM 16 and mini-BEAM 17, 18 result in poor and unpredictable mobilization. Chemotherapy scoring systems 19, 20 can predict patients at risk of mobilization failure for whom new strategies are required.
While several mobilization regimens have been reported, single agent cyclophosphamide (1-7 g/m 2 ) followed by filgrastim (G-CSF) remains one of the most common. It has been reported that combination chemotherapy with cyclophosphamide, etoposide and G-CSF (C+E) is superior to cyclophosphamide and G-CSF (C alone), and may add an additional anti-lymphoma effect. 21 We explored the use of C+E given the difficulty with mobilization in heavily pretreated lymphoma patients using C alone, the more predictable timing of mobilization following C+E than with ESHAP or DHAP chemotherapy, and the ability to deliver C+E as an out-patient. Here, we report our experience with the C+E mobilizing regimen. To overcome some of the biases associated with historic comparisons, we have performed a matched cohort analysis comparing patients mobi-lized with C+E versus C alone, matched for factors likely to influence PBSC collection efficiency.
Materials and methods

Patients
Consecutive patients undergoing their first PBSC mobilization with C+E were identified from the ASCT database. Only patients with Hodgkin's disease and non-Hodgkin's lymphoma were considered. Matched controls were selected with a cohort of all lymphoma patients mobilized with C alone from January 1999 to December 2000. This allowed comparison with a cohort of patients with identical PBSC collection techniques (CD34 + enumeration, commencement of apheresis depending on peripheral blood CD34 + count, apheresis procedure). Data abstracted included patient demographics, disease status and prior therapy, daily CD34
+ yields and days of apheresis, and if transplanted, time to hematopoietic recovery, transfusion requirements and days of hospitalization.
Matching of patients
Patients were matched for diagnosis (Hodgkin's disease vs non-Hodgkin's lymphoma), prior radiotherapy to the axial skeleton and a previously validated chemotherapy score (within a limit of Ϯ3). 19 If more than one patient potentially matched, the patient with the most recent mobilization date was chosen. Matching was performed in a manner blinded to all potential outcomes.
The chemotherapy score, as outlined in Table 1 , was slightly modified from that reported by Drake et al, 19 with the addition of a score of two for cytarabine, which was not included in the original scoring system. This was in order to accommodate the majority of non-Hodgkin's lymphoma patients salvaged with ESHAP or DHAP, both cytarabine-containing regimens. The modified score was then applied to the 1999/2000 cohort of patients mobilized with C alone to validate its utility as a predictor of PBSC mobilization with that regimen.
Mobilization and transplantation
Patients mobilized with C+E received cyclophosphamide 2.5 g/m 2 i.v. on day 1 and etoposide 200 mg/m 2 once daily i.v. on days 1-3 on an outpatient basis. The C alone group Table 1 Derivation of chemotherapy score (modified from Drake et al 19 )
Toxicity grade Drugs
Vincristine, vinblastine, bleomycin, interferon 2 Cyclophosphamide, anthracyclines, cisplatin, etoposide, cytarabine 3
Chlorambucil, procarbazine 4
Melphalan, carmustine, mechlorethamine, lomustine Score = (number of cycles of each drug) ϫ (toxicity grade).
received cyclophosphamide 2.5 g/m 2 i.v. on day 1. Both regimens were followed by G-CSF 10 g/kg once daily s.c., starting on day 4 for C alone patients and day 6 for C+E patients, until harvesting was complete. PBSC collection commenced on day 13 (C+E) or day 11 (C alone) provided that the peripheral blood CD34
+ count was у5 cells/l. PBSCs were collected by continuous apheresis, processing three blood volumes, using the Cobe Spectra (Lakewood, CO, USA).
Patients undergoing autologous transplantation received etoposide 60 mg/kg i.v. over 5 or 32 h day Ϫ4 and melphalan 180 mg/m 2 over 30 min on day Ϫ3. Peripheral blood stem cells were infused on day 0. Routine transfusion triggers included platelets Ͻ10 ϫ 10 9 /l and hemoglobin Ͻ80 g/l. G-CSF 300 g s.c. was commenced on day 7.
Statistical analysis
In validating the modified chemotherapy score in the 1999/2000 cohort, the score was categorized as a binary variable (Ͻ42 vs у42), the cutoff corresponding to the 50th percentile for this group of patients. The chi-square test was used to determine the effect of the chemotherapy score on the proportion of patients achieving a CD34
+ yield of у2 ϫ 10 6 /kg. In the matched cohort analysis, study endpoints included: the proportion of patients achieving minimum (у2 ϫ 10 6 /kg CD34 + ) and target (у5 ϫ 10 6 /kg CD34 + ) collections; the proportion of patients achieving these thresholds in one apheresis; total CD34 + yield; time to recovery of neutrophils Ͼ0.5 ϫ 10 9 /l and platelets Ͼ20 ϫ 10 9 /l, and days of hospitalization. The impact of C+E on these endpoints was assessed using McNemar's test for categorical variables and the sign-rank test for continuous variables. All analyses were performed using the STATA (University of Texas) statistical software package. Summary statistics use median values with ranges in brackets.
Results
Patient characteristics and matching
Forty-eight consecutive lymphoma patients were mobilized with C+E between July 2000 and October 2001. Of these, 38 could be successfully matched as detailed in the materials and methods section. Ten could not be matched due mainly to the recent use of a gemcitabine-based salvage regimen that precluded the assignment of a chemotherapy score to these patients. The characteristics of these 38 patients and their matched controls along with the entire 1999/2000 cohort mobilized with C alone are detailed in Table 2 . When C+E patients were compared with their matched C alone recipients, there was no difference in age, sex, disease status, marrow involvement or number of prior chemotherapy regimens.
Validation of 'modified' chemotherapy score
Of the 98 patients in the entire C-mobilized cohort, 45% had a chemotherapy score Ͻ42 (low score) and 55% scored у42 (high score). This score was able to identify patients at increased risk of mobilization failure; a graft of у2 ϫ 10 6 /kg was obtained in 88% of patients with a score Ͻ42, compared to 56% of patients with a score у42 (P Ͻ 0.01).
PBSC collections
Mobilization results for the matched patients and the entire C-mobilized cohort are shown in Table 3 . Detailed is the total CD34
+ yield and the proportion of patients obtaining both minimum and target PBSC numbers. The total CD34 + yield was significantly greater for C+E compared to C alone (6.35 vs 3.3 ϫ 10 6 /kg, P Ͻ 0.01).
Minimum threshold (у2 ϫ 10 6 /kg CD34 + ): While the proportion of patients achieving a minimum CD34 + threshold C+E= cyclophosphamide + etoposide; C = cyclophosphamide alone; HD = Hodgkin's disease; NHL = non-Hodgkin's lymphoma. *P Ͻ 0.05 by matched pairs analysis (C+E vs C).
Bone Marrow Transplantation appears to have improved with the use of C+E compared to the previous C-mobilized cohort (70% vs 82%, P = 0.18), the matched analysis demonstrates no difference in this regard. Thus, the matching process is likely to be correcting for the lower chemotherapy score in C+E patients compared to patients mobilized with C alone (see Table 2 ). Significantly more patients obtained the minimum threshold number of CD34 + cells after a single apheresis when mobilized with C+E (61% vs 32%, P Ͻ 0.01). In subgroup analysis C+E was not superior to C alone according to tumor type or chemotherapy score in achieving a minimum threshold. The chemotherapy score was predictive of mobilization failure for all patients in the matched cohorts (9% if score Ͻ42 vs 32% if score у42, P = 0.01). Patients with Hodgkin's disease mobilized better than patients with nonHodgkin's lymphoma, likely reflecting the type of prior treatment given to these patients (median score 34 for Hodgkin's disease vs 42 for non-Hodgkin's lymphoma; Table 3 ).
Target threshold (у5 ϫ 10 6 /kg CD34 + ): C+E was superior to C alone in obtaining an optimal CD34
+ yield (56% vs 34%, P = 0.04), and this target could be collected with a single leukapheresis in significantly more patients (45% vs 13%, P Ͻ 0.01). This improved collection efficiency, however, appears to be confined to those patients with low chemotherapy scores, and does not appear to benefit those with a score у42 (Table 3) .
Of the 10 patients who could not be matched, nine achieved a minimum threshold of у2 ϫ 10 6 /kg CD34 + cells using C+E as a mobilizing regimen. Eight of these had received gemcitabine-based salvage chemotherapy and their median CD34
+ yield was 17.5 ϫ 10 6 /kg (range, 1.6-37.7 ϫ 10 6 /kg).
Engraftment
Days to platelet and neutrophil engraftment, transfusion requirements and length of hospital stay are detailed in Table 4 . The C+E mobilization regimen was not superior to C alone for any of these parameters.
Discussion
The collection of adequate numbers of PBSCs is a critical step in the management of lymphoma patients requiring autotransplantation. The combination of cyclophosphamide Table 4 Engraftment and hospitalization
C+E C (matched controls)
Platelets Ͼ20 (days) 10 ( and G-CSF is a well tolerated outpatient regimen that has been used extensively for stem cell mobilization. 17, [22] [23] [24] [25] It is successful in the majority of patients, but a significant proportion cannot attain an adequate graft, especially those predicted to be 'hard to mobilize'. Similarly, improvements in the efficiency of the mobilization procedure could lead to cost savings and reduced morbidity. We have demonstrated in this matched cohort study that C+E is more efficient, with increased progenitor yields and reduced days of apheresis, compared to C alone. There was, however, no improvement in the proportion of patients who obtained a minimum threshold (у2 ϫ 10 6 /kg CD34 + ) harvest in order to proceed safely to ASCT. Patients mobilized with C alone required more aphereses compared to C+E, but were still able to eventually reach the minimum threshold and had similar hematopoietic recovery following high-dose chemotherapy.
The use of cyclophosphamide and etoposide has been reported in a randomized study by Schwartzberg et al + cells. 27 The addition of cisplatin resulted in excessive toxicity with no additional benefit in mobilization.
One concern with the use of etoposide in the mobilization regimen is its potential contribution to an increased risk of secondary acute leukemia after ABMT. 28, 29 We used a relatively low dose of etoposide (total 600 mg/m 2 ), but the long-term safety and leukemia risk of this lower dose will require additional follow-up. Ultimately, separating the contributions of DNA damaging agents (alkylating agents such as cyclophosphamide and topoisomerase II inhibitors such as etoposide) in salvage and mobilization chemotherapy, in addition to the high-dose therapy itself, with regard to this leukemic risk may be problematic.
It is difficult to compare the results of C+E to other mobilizing regimens because of the heterogeneous nature of the study populations, the lack of randomized trials and, until recently, the lack of standardization in CD34 + enumeration. 2 Improved PBSC mobilization has been reported with higher doses of cyclophosphamide, 23, 26, 30 although morbidity from the procedure also rises. In a matched cohort study of ESHAP vs intermediate-dose cyclophosphamide, Watts et al 31 reported that ESHAP significantly improved the proportion of patients obtaining a CD34 + yield Ͼ2 ϫ 10 6 /kg in one apheresis (72% vs 22%) and improved progenitor yields on the first day of apheresis. The total number of progenitors collected, and median time to platelet and neutrophil engraftment, were similar for both groups. A number of chemotherapy-based mobilizing regimens has been reported in lymphoma patients, [32] [33] [34] [35] however, only one is a randomized comparison to cyclophosphamide alone. 32 That trial compared ifosfamide 10 g/m 2 and GM-CSF to cyclophosphamide 4 g/m 2 and GM-CSF and reported similar CD34 + yields, but improved neutrophil engraftment and less toxicity with cyclophosphamide. Only one randomized controlled trial has compared a chemotherapy-based regimen (cyclophosphamide 5g/m 2 + G-CSF) with a cytokine alone (G-CSF alone). 36 This demonstrated no difference in engraftment or CD34
+ yields, although the number of patients was small, and no patients progressed on salvage chemotherapy, suggesting a somewhat atypical lymphoma population. This trial highlighted the importance of considering engraftment rather than CD34 + yield as the clinical endpoint of interest.
Our study is limited by not being a randomized comparison, but uses a matched-pairs analysis based on factors known to influence mobilization efficiency to help overcome some of the biases associated with historical cohort comparisons. The difference in PBSC yields between the matched controls and the entire cohort from which they were selected illustrates the importance of appropriate matching in such comparisons of new mobilizing regimens. While a chemotherapy score 19 was primarily used in our study to match patients for prior chemotherapy exposure, it was also able to predict those at increased risk of mobilization failure. Furthermore, it was those patients predicted to be 'hard to mobilize' who benefited least from the addition of etoposide to the mobilizing regimen. Stiff et al 37 have explored the addition of stem cell factor to G-CSF in heavily pretreated lymphoma patients. This produced improved CD34
+ yields compared to those mobilized with G-CSF alone, although the proportion who achieved Ͼ1 ϫ 10 6 /kg CD34 + cells was not significantly different. In summary, C+E mobilizing chemotherapy improves the efficiency of PBSC collection compared to C alone by reducing days of apheresis and increasing progenitor yields. This effect, however, is largely confined to those patients with less prior chemotherapy and does not appear to benefit more heavily pre-treated patients predicted to be 'hard to mobilize'. The chemotherapy scoring system we used can identify those patients where new strategies are required for successful stem cell collection. We are currently prospectively evaluating the combination of cyclophosphamide, G-CSF and stem cell factor as a mobilizing regimen in this high-risk lymphoma population.
